New Diagnostic Test for Pancreatic Cancer Is Based on the Differential Expression of Select miRNAs in Plasma and Bile
|
By LabMedica International staff writers Posted on 10 Nov 2014 |
|
A panel of microRNA (miRNA) biomarkers was assembled from the pool of miRNAs present in the blood of most pancreatic cancer patients that may serve as a diagnostic tool and an indicator of the disease’s aggressiveness.
Pancreatic cancer is the fourth most common cause of cancer death in the Western world. The prognosis is poor, with one- and five-year survival rates of only 20% and 6%, respectively. Therefore, markers of the disease that could help with early diagnosis are needed to improve the prognosis. Statistics from the [US] National Cancer Institute (Bethesda, MD, USA) show that only about 6% of people with pancreatic cancer survive more than five years after diagnosis. In 2013 an estimated 45,220 new cases of pancreatic cancer were expected to be diagnosed with more than 38,460 of the cases being fatal.
MiRNAs are snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.
Investigators at Indiana University (Indianapolis, USA) determined miRNA levels in blood or bile obtained from 215 patients with pancreatic ductal adenocarcinoma (PDAC) or from controls. Panels were derived from the differential expression of 10 candidate miRNAs in the samples. MiRNAs that had excellent accuracy for inclusion in regression models were selected. Total RNA was isolated from samples using Trizol-LS (Life Technologies; Carlsbad, CA, USA). Complementary DNA was generated using 10 ng of RNA in conjunction with miRNA-10b, -21, -30c, -106b, -132, -155, -181a, -181b, -196a, -212, or -425-5p reverse transcription primers and a miRNA reverse transcription kit (Life Technologies). Quantitative PCR was performed for each miRNA using Taqman (Life Technologies) miRNA expression assay reagents.
Results revealed that increased expression of miRNA-10b, -155, and -106b in plasma appeared to be highly accurate for diagnosing pancreatic cancer.
Senior author Dr. Murray Korc, professor of cancer research at Indiana University, said, “This is a new finding that extends previous knowledge in this field. The key new feature here is that there is a panel of microRNAs that can be measured accurately in the plasma component of blood to determine if a patient has pancreatic cancer. It may be possible to use a blood test to screen individuals who are at high risk for developing pancreatic cancer. We are planning to conduct such studies. It will be important to identify additional markers and to assess how useful a panel of such markers would be for the early diagnosis of this cancer. Based on our findings, this test could also be useful to differentiate between pancreatic cancer and chronic pancreatitis.”
The study was published in the October 28, 2014, online edition of the American Journal of Gastroenterology.
Related Links:
National Cancer Institute
Indiana University
Life Technologies
Pancreatic cancer is the fourth most common cause of cancer death in the Western world. The prognosis is poor, with one- and five-year survival rates of only 20% and 6%, respectively. Therefore, markers of the disease that could help with early diagnosis are needed to improve the prognosis. Statistics from the [US] National Cancer Institute (Bethesda, MD, USA) show that only about 6% of people with pancreatic cancer survive more than five years after diagnosis. In 2013 an estimated 45,220 new cases of pancreatic cancer were expected to be diagnosed with more than 38,460 of the cases being fatal.
MiRNAs are snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.
Investigators at Indiana University (Indianapolis, USA) determined miRNA levels in blood or bile obtained from 215 patients with pancreatic ductal adenocarcinoma (PDAC) or from controls. Panels were derived from the differential expression of 10 candidate miRNAs in the samples. MiRNAs that had excellent accuracy for inclusion in regression models were selected. Total RNA was isolated from samples using Trizol-LS (Life Technologies; Carlsbad, CA, USA). Complementary DNA was generated using 10 ng of RNA in conjunction with miRNA-10b, -21, -30c, -106b, -132, -155, -181a, -181b, -196a, -212, or -425-5p reverse transcription primers and a miRNA reverse transcription kit (Life Technologies). Quantitative PCR was performed for each miRNA using Taqman (Life Technologies) miRNA expression assay reagents.
Results revealed that increased expression of miRNA-10b, -155, and -106b in plasma appeared to be highly accurate for diagnosing pancreatic cancer.
Senior author Dr. Murray Korc, professor of cancer research at Indiana University, said, “This is a new finding that extends previous knowledge in this field. The key new feature here is that there is a panel of microRNAs that can be measured accurately in the plasma component of blood to determine if a patient has pancreatic cancer. It may be possible to use a blood test to screen individuals who are at high risk for developing pancreatic cancer. We are planning to conduct such studies. It will be important to identify additional markers and to assess how useful a panel of such markers would be for the early diagnosis of this cancer. Based on our findings, this test could also be useful to differentiate between pancreatic cancer and chronic pancreatitis.”
The study was published in the October 28, 2014, online edition of the American Journal of Gastroenterology.
Related Links:
National Cancer Institute
Indiana University
Life Technologies
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Steam Sterilizer
Hi Vac II Line
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Latest Pathology News
- AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
- AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
- Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
- New Chromogenic Culture Media Enable Rapid Detection of Candida Infections
- AI-Powered Tool to Transform Dermatopathology Workflow
- AI Tool Predicts Chemotherapy Response from Biopsy Slides
- Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
- World’s First Optical Microneedle Device to Enable Blood-Sampling-Free Clinical Testing
- Novel mcPCR Technology to Transform Testing of Clinical Samples
- Pathogen-Agnostic Testing Reveals Hidden Respiratory Threats in Negative Samples
- Molecular Imaging to Reduce Need for Melanoma Biopsies
- Urine Specimen Collection System Improves Diagnostic Accuracy and Efficiency
- AI-Powered 3D Scanning System Speeds Cancer Screening
- Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples
- New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow
- AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear
Channels
Clinical Chemistry
view channel
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read more
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Molecular Diagnostics
view channel
RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
Many patients with advanced solid tumors exhaust broad DNA panel testing yet still lack biomarkers that match guideline-recommended therapies, limiting access to targeted options. Expanding molecular profiling... Read more
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Immunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microbiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read more
Technology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read more
Industry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more
